Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 803 results for "daiichi sankyo company"

Daiichi Sankyo Presents Phase 1 Data for MDM2 Inhibitor DS-303...

- Preliminary results of phase 1 study demonstrate once-daily oral dosing of DS-3032 appears to be promising approach to treat relapsed/refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) - Single-agent activity of ... PR Newswire, 16 hours ago
[x]  

13 images for daiichi sankyo company

World Pharma News, 1 month ago
Livemint.com, 1 month ago
Contract Pharma, 2 months ago
Nasdaq, 4 months ago
Nasdaq, 4 months ago
Reuters India, 6 months ago
Business Insider, 6 months ago
Reuters India, 7 months ago
Yahoo! India, 6 months ago
Channel NewsAsia, 6 months ago
Livemint.com

Ajanta Pharma launches BP lowering tablets in US

The company's product is a generic version of Daiichi Sankyo's Azor tablets Drug firm Ajanta Pharma has launched blood pressure lowering tablets in the US market. After the approval of the United States Food and Drug Administration (US FDA), the ...
 Express Pharma1 month ago Sun Pharma launches authorized generics of 4 Daiichi Sankyo's drugs in US  Livemint.com1 month ago Sun Pharma launches blood pressure drugs in US; shares up nearly 1%  DNA1 month ago Sun Pharma launches generic versions of Daiichi Sankyo's high blood pressure drugs in US  Economic Times1 month ago
[x]  
StatNews.com

Daiichi Sankyo Partnering Deals and Alliances 2010 to 2016 - Research and Markets

DUBLIN--( BUSINESS WIRE )-- Research and Markets has announced the addition of the "Daiichi Sankyo Partnering Deals and Alliances 2010 to 2016" company profile to their offering. The Partnering Deals and Alliance since 2010 report provides an ...
 Business Wire2 weeks ago Generic Drugs Market Key Companies Analysis 2016 to 2020  Before It's News1 month ago Global Acute Ischemic Stroke Therapeutics Report 2016: Pipeline Review of 17 Companies & 27 drug Molecules - Research and Markets  Minyanville1 month ago Tetanus Therapeutics Drugs Profile and Key Companies Pipeline Review, H2 2016  Before It's News1 month ago
[x]  

Daiichi Sankyo, Inspirion collaborate to commercialise MorphaBond formulated with SentryBond abuse-deterrent technology

Daiichi Sankyo, Inc. and Inspirion Delivery Sciences LLC (Inspirion) have entered into a strategic collaboration agreement in the US to commercialize FDA-approved MorphaBond (morphine sulfate) extended-release tablets, CII. The agreement also ...
 PharmaBiz1 month ago Daiichi Sankyo & Inspirion Delivery Sciences Announce Licensing Agreement  Drug Development & Delivery1 month ago BRIEF-Daiichi Sankyo Co and Inspirion Delivery Sciences LLC Announce U.S. Licensing Agreement for MorphaBond  Reuters UK1 month ago Daiichi Sankyo and Inspirion Delivery Sciences Announce U.S. Licensing Agreement for MorphaBond Formulated with SentryBond Abuse-Deterrent Technology  FirstWord Pharma1 month ago
[x]  

Daiichi Sankyo Company, Limited - Product Pipeline Review - 2016

Summary 's, ' ', provides an overview of the Daiichi Sankyo Company, Limited's pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Daiichi Sankyo Company, Limited, ...
 Global Information Inc3 weeks ago Daiichi Sankyo HY Profit Down  RTTNews.com1 month ago UPDATED: Daiichi adds abuse-deterrent opioid to pain portfolio  FiercePharma1 month ago The writing of this report was sponsored by Daiichi-Sankyo. The company had no input into the content of the report but did examine it for ABPI compliance before publication.  Arrhythmia Watch1 month ago
Ariva.de

Daiichi Sankyo webcast presentation now available for on-demand viewing: dbVIC - Deutsche Bank ADR Virtual Investor Conference

Company invites individual and institutional investors, as well as advisors, to log-on to view the presentation TOKYO, Nov. 21, 2016 /CNW/ --Daiichi Sankyo Co., Ltd (JP: 4568.T, OTC: DSNKY) based in Tokyo, and focused on pharmaceutical business, ...
 4 Traders2 weeks ago Daiichi Sankyo to present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference on Thursday, November 17th, 2016  International Business Times3 weeks ago DAIICHI SANKYO : to present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference on Thursday, November 17th, 2016  4 Traders3 weeks ago
[x]  

Pieris Pharmaceuticals to Receive GLP Tox Milestone Payment in Daiichi Sankyo Collaboration

BOSTON, MA--(Marketwired - October 26, 2016) - Pieris Pharmaceuticals, Inc. ( NASDAQ: PIRS ), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for cancer and other ...
 Minyanville1 month ago Pieris Pharmaceuticals Reports Financial Results and Provides Corporate Update for the Third Quarter Ended September 30, 2016  Canadian Business Journal3 weeks ago PIERIS PHARMACEUTICALS : Reports Financial Results and Provides Corporate Update for the Third Quarter Ended September 30, 2016  4 Traders3 weeks ago BRIEF-Pieris Pharmaceuticals to receive GLP Tox payment in Daiichi Sankyo collaboration  Reuters UK1 month ago
[x]  
International Business Times

Torrent Pharmaceuticals Ltd. v. Daiichi Sankyo Inc.; Alembic Pharmaceuticals Ltd. v. Daiichi Sankyo Co. Ltd; Aurobindo Pharmaceuticals Ltd. v. Daiichi Sankyo Inc.

N.D. Ill. (2016) Fitzpatrick Obtains Dismissal on Behalf of Daiichi Sankyo of Three Generic Drug Companies Declaratory Judgment Actions On July 25, 2016, Fitzpatrick succeeded in obtaining dismissal of complaints brought by Torrent, Alembic ...
 Fitzpatrickcella.com2 weeks ago Daiichi Sankyo Healthcare Co Ltd in Consumer Health (Japan)  MarketResearch.com2 weeks ago Rigel to Present at Jefferies 2016 London Healthcare Conference  International Business Times3 weeks ago ArQule Reports Third Quarter 2016 Financial Results  Ariva.de4 weeks ago
[x]  

FDA OKs Teva's generic version of blood pressure med Tribenzor

The FDA approves Teva Pharmaceutical Industries' (NASDAQ: TEVA ) generic version of Daiichi Sankyo's ( OTCPK:DSKYF )( OTCPK:DSNKY ) TRIBENZOR (olmesartan medoxomil, amlodipine, hydrochlorothiazide) for the treatment of hypertension. Final launch ...
 Seeking Alpha4 weeks ago Teva Announces Approval of Generic Tribenzor┬« in the United States  Wallstreet Online4 weeks ago
[x]  

Daiichi Sankyo Announces New Subgroup Analyses of Once-Daily SAVAYSA® (edoxaban) in Patients with Non-Valvular Atrial Fibrillation to be Presented at AHA Scientific Sessions 2016

PARSIPPANY, N.J., Nov. 7, 2016 /PRNewswire/ -- ., (hereafter, Daiichi Sankyo) today announced the presentation of six abstracts at the American Heart Association (AHA) Scientific Sessions 2016, November 12-16, New Orleans, Louisiana. A new subgroup ...
 International Business Times4 weeks ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less